Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Treasury Shares (2022 - 2025)

Ocular Therapeutix has reported Treasury Shares over the past 4 years, most recently at $4.4 million for Q4 2025.

  • Quarterly results put Treasury Shares at $4.4 million for Q4 2025, up 28.61% from a year ago — trailing twelve months through Dec 2025 was $4.4 million (up 28.61% YoY), and the annual figure for FY2025 was $4.4 million, up 28.61%.
  • Treasury Shares for Q4 2025 was $4.4 million at Ocular Therapeutix, up from $3.4 million in the prior quarter.
  • Over the last five years, Treasury Shares for OCUL hit a ceiling of $4.4 million in Q4 2025 and a floor of $1.1 million in Q4 2022.
  • Median Treasury Shares over the past 4 years was $2.5 million (2023), compared with a mean of $2.6 million.
  • Biggest five-year swings in Treasury Shares: skyrocketed 108.29% in 2024 and later rose 28.61% in 2025.
  • Ocular Therapeutix's Treasury Shares stood at $1.1 million in 2022, then skyrocketed by 48.93% to $1.6 million in 2023, then skyrocketed by 108.29% to $3.4 million in 2024, then rose by 28.61% to $4.4 million in 2025.
  • The last three reported values for Treasury Shares were $4.4 million (Q4 2025), $3.4 million (Q4 2024), and $1.6 million (Q4 2023) per Business Quant data.